Jehn Ulrich, Kortenhorn Anja, Schütte-Nütgen Katharina, Thölking Gerold, Westphal Florian, Strauss Markus, Wennmann Dirk-Oliver, Pavenstädt Hermann, Suwelack Barbara, Görlich Dennis, Reuter Stefan
Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of Muenster, 48149 Muenster, Germany.
Department of Medicine C, Division of Cardiology and Angiology, University Hospital of Muenster, 48149 Muenster, Germany.
J Clin Med. 2022 Jan 27;11(3):654. doi: 10.3390/jcm11030654.
Kidney transplant (KTx) recipients are a high-risk population for osteoporotic fractures. We herein aim to identify the role of pre-transplant parathyroidectomy (PTX) and other modifiable factors associated with osteoporotic fractures in KTx recipients. We conducted a retrospective study involving 711 adult patients (4608 patient-years) who were transplanted at our center between January 2007 and June 2015. Clinical data were extracted from patients' electronic medical records. Different laboratory and clinical parameters for mineral bone disease (MBD) and osteoporosis, including medication, were evaluated. We chose fracture events unrelated to malignancies or adequate trauma as the primary endpoint. Osteoporotic fractures occurred in 47 (6.6%) patients (median 36.7 months, IQR 45.9) after KTx (fracture incidence of 10 per 1000 person-years). Prior to KTx, subtotal PTX was performed in 116 patients (16.3%, median time 4.2 years before KTx, IQR 5.0). Of the patients with fracture ( = 47), only one (2.2%) patient had previously undergone PTX. After adjusting for the known fracture risk factors MBD and osteoporosis, PTX remained a protective factor against fractures (HR 0.134, CI 0.018-0.991, = 0.049). We observed a reduced risk for pathological fractures in KTx patients who underwent PTX, independent from elevated parathyroid hormone at the time of KTx or afterwards.
肾移植(KTx)受者是骨质疏松性骨折的高危人群。我们旨在确定移植前甲状旁腺切除术(PTX)以及其他与KTx受者骨质疏松性骨折相关的可改变因素的作用。我们进行了一项回顾性研究,纳入了2007年1月至2015年6月在我们中心接受移植的711例成年患者(4608患者年)。临床数据从患者的电子病历中提取。评估了包括药物治疗在内的不同的矿物质骨病(MBD)和骨质疏松症的实验室及临床参数。我们将与恶性肿瘤无关或非严重创伤引起的骨折事件作为主要终点。KTx术后47例(6.6%)患者发生骨质疏松性骨折(中位时间36.7个月,四分位间距45.9)(骨折发生率为每1000人年10例)。在KTx术前,116例患者(16.3%)接受了次全PTX(中位时间为KTx术前4.2年,四分位间距5.0)。在发生骨折的患者(n = 47)中,只有1例(2.2%)患者之前接受过PTX。在对已知的骨折危险因素MBD和骨质疏松症进行校正后,PTX仍然是预防骨折的保护因素(风险比0.134,可信区间0.018 - 0.991,P = 0.049)。我们观察到接受PTX的KTx患者发生病理性骨折的风险降低,这与KTx时或术后甲状旁腺激素升高无关。